Cargando…
Non-STEMI vs. STEMI Cardiogenic Shock: Clinical Profile and Long-Term Outcomes
Cardiogenic shock (CS) is a severe complication of acute myocardial infarction (AMI). In AMI-CS, the ST segment deviation on ECG may be elevated (STEMI-CS) or non-elevated (NSTEMI-CS), which may influence prognosis. Our aim was to analyze the clinical profile, acute-phase prognosis, and long-term ou...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224589/ https://www.ncbi.nlm.nih.gov/pubmed/35743628 http://dx.doi.org/10.3390/jcm11123558 |
_version_ | 1784733404719218688 |
---|---|
author | Martínez, María José Rueda, Ferran Labata, Carlos Oliveras, Teresa Montero, Santiago Ferrer, Marc El Ouaddi, Nabil Serra, Jordi Lupón, Josep Bayés-Genís, Antoni García-García, Cosme |
author_facet | Martínez, María José Rueda, Ferran Labata, Carlos Oliveras, Teresa Montero, Santiago Ferrer, Marc El Ouaddi, Nabil Serra, Jordi Lupón, Josep Bayés-Genís, Antoni García-García, Cosme |
author_sort | Martínez, María José |
collection | PubMed |
description | Cardiogenic shock (CS) is a severe complication of acute myocardial infarction (AMI). In AMI-CS, the ST segment deviation on ECG may be elevated (STEMI-CS) or non-elevated (NSTEMI-CS), which may influence prognosis. Our aim was to analyze the clinical profile, acute-phase prognosis, and long-term outcomes of CS relative to the ST pattern on admission. In a prospective registry of 4647 AMI patients admitted to the intensive cardiac care unit of a university hospital between 2010 and 2019, we compared the clinical characteristics, 30-days case fatality, and long-term outcomes of AMI-CS, based on the presence of ST-segment deviation. AMI-CS developed in 239 (5.1%) patients (26.4% women): 190 (79.5%) STEMI-CS and 49 (20.5%) NSTEMI-CS. The mean age was 69.7 years. The STEMI-CS patients had larger infarcts and more mechanical complications than the NSTEMI-CS patients. The NSTEMI-CS patients had a greater prevalence of hypertension, diabetes, peripheral vascular disease, previous cardiovascular comorbidities, three-vessel disease, and left main disease than the STEMI-CS patients. The STEMI-CS patients had higher 30-day mortality than the NSTEMI-CS (59.5% vs. 36.7%; p = 0.004), even after multivariable adjustment (HR 1.91; 95% CI 1.16–3.14), but no differences in mortality were observed at 3 years. In conclusion, the 30-day case-fatality is higher in STEMI-CS, but the long-term outcome is similar in both groups. |
format | Online Article Text |
id | pubmed-9224589 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92245892022-06-24 Non-STEMI vs. STEMI Cardiogenic Shock: Clinical Profile and Long-Term Outcomes Martínez, María José Rueda, Ferran Labata, Carlos Oliveras, Teresa Montero, Santiago Ferrer, Marc El Ouaddi, Nabil Serra, Jordi Lupón, Josep Bayés-Genís, Antoni García-García, Cosme J Clin Med Article Cardiogenic shock (CS) is a severe complication of acute myocardial infarction (AMI). In AMI-CS, the ST segment deviation on ECG may be elevated (STEMI-CS) or non-elevated (NSTEMI-CS), which may influence prognosis. Our aim was to analyze the clinical profile, acute-phase prognosis, and long-term outcomes of CS relative to the ST pattern on admission. In a prospective registry of 4647 AMI patients admitted to the intensive cardiac care unit of a university hospital between 2010 and 2019, we compared the clinical characteristics, 30-days case fatality, and long-term outcomes of AMI-CS, based on the presence of ST-segment deviation. AMI-CS developed in 239 (5.1%) patients (26.4% women): 190 (79.5%) STEMI-CS and 49 (20.5%) NSTEMI-CS. The mean age was 69.7 years. The STEMI-CS patients had larger infarcts and more mechanical complications than the NSTEMI-CS patients. The NSTEMI-CS patients had a greater prevalence of hypertension, diabetes, peripheral vascular disease, previous cardiovascular comorbidities, three-vessel disease, and left main disease than the STEMI-CS patients. The STEMI-CS patients had higher 30-day mortality than the NSTEMI-CS (59.5% vs. 36.7%; p = 0.004), even after multivariable adjustment (HR 1.91; 95% CI 1.16–3.14), but no differences in mortality were observed at 3 years. In conclusion, the 30-day case-fatality is higher in STEMI-CS, but the long-term outcome is similar in both groups. MDPI 2022-06-20 /pmc/articles/PMC9224589/ /pubmed/35743628 http://dx.doi.org/10.3390/jcm11123558 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Martínez, María José Rueda, Ferran Labata, Carlos Oliveras, Teresa Montero, Santiago Ferrer, Marc El Ouaddi, Nabil Serra, Jordi Lupón, Josep Bayés-Genís, Antoni García-García, Cosme Non-STEMI vs. STEMI Cardiogenic Shock: Clinical Profile and Long-Term Outcomes |
title | Non-STEMI vs. STEMI Cardiogenic Shock: Clinical Profile and Long-Term Outcomes |
title_full | Non-STEMI vs. STEMI Cardiogenic Shock: Clinical Profile and Long-Term Outcomes |
title_fullStr | Non-STEMI vs. STEMI Cardiogenic Shock: Clinical Profile and Long-Term Outcomes |
title_full_unstemmed | Non-STEMI vs. STEMI Cardiogenic Shock: Clinical Profile and Long-Term Outcomes |
title_short | Non-STEMI vs. STEMI Cardiogenic Shock: Clinical Profile and Long-Term Outcomes |
title_sort | non-stemi vs. stemi cardiogenic shock: clinical profile and long-term outcomes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224589/ https://www.ncbi.nlm.nih.gov/pubmed/35743628 http://dx.doi.org/10.3390/jcm11123558 |
work_keys_str_mv | AT martinezmariajose nonstemivsstemicardiogenicshockclinicalprofileandlongtermoutcomes AT ruedaferran nonstemivsstemicardiogenicshockclinicalprofileandlongtermoutcomes AT labatacarlos nonstemivsstemicardiogenicshockclinicalprofileandlongtermoutcomes AT oliverasteresa nonstemivsstemicardiogenicshockclinicalprofileandlongtermoutcomes AT monterosantiago nonstemivsstemicardiogenicshockclinicalprofileandlongtermoutcomes AT ferrermarc nonstemivsstemicardiogenicshockclinicalprofileandlongtermoutcomes AT elouaddinabil nonstemivsstemicardiogenicshockclinicalprofileandlongtermoutcomes AT serrajordi nonstemivsstemicardiogenicshockclinicalprofileandlongtermoutcomes AT luponjosep nonstemivsstemicardiogenicshockclinicalprofileandlongtermoutcomes AT bayesgenisantoni nonstemivsstemicardiogenicshockclinicalprofileandlongtermoutcomes AT garciagarciacosme nonstemivsstemicardiogenicshockclinicalprofileandlongtermoutcomes |